This pain occurs in about 50% of women who survived breast cancer [38] and is described as widespread musculoskeletal pain, also called "aromatase inhibitor musculoskeletal syndrome or AIMSS." This pain persists even after stopping the drug. Here, CYP19A1 is linked to breast carcinoma.